Reynolds C Patrick, Maurer Barry J
USC-CHLA Institute for Pediatric Clinical Research, University of Southern California and Childrens Hospital Los angeles, Los Angeles, CA, USA.
Methods Mol Med. 2005;110:173-83. doi: 10.1385/1-59259-869-2:173.
The mainstay of clinical antineoplastic chemotherapy is multiagent combinations, most of which were developed empirically. Because of the desire to speed research and decrease costs, there is increasing interest in moving new drugs into clinical trials in potentially active combinations based on preclinical testing data. Different mathematical models have been proposed for evaluating drug interactions, which can be classified as synergistic (combinations demonstrating greater than the additive activity expected from each agent alone), additive, or antagonistic (drugs showing less activity in combination than expected from the sum of each agent alone). Here, we briefly review some of the principles for testing cytotoxic drug interactions. We focus this review on application of the Combination Index method (as developed by Chou and colleagues) in the evaluation of drug interactions in cell culture assays.
临床抗肿瘤化疗的主要手段是联合使用多种药物,其中大多数是凭经验研发的。出于加快研究速度和降低成本的愿望,基于临床前测试数据,将新药以潜在的活性组合形式推进临床试验的兴趣与日俱增。已经提出了不同的数学模型来评估药物相互作用,这些模型可分为协同(组合显示出的活性大于每种药物单独预期的相加活性)、相加或拮抗(药物组合时显示出的活性低于每种药物单独活性之和预期的活性)。在此,我们简要回顾一些测试细胞毒性药物相互作用的原则。本综述重点关注联合指数法(由Chou及其同事开发)在细胞培养试验中药物相互作用评估中的应用。